Literature DB >> 11292678

Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease.

E Bezard1, A R Crossman, C E Gross, J M Brotchie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11292678     DOI： 10.1096/fj.00-0637fje

Source DB:  PubMed          Journal:  FASEB J        ISSN： 0892-6638            Impact factor:   5.191


× No keyword cloud information.
  14 in total

1.  Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Authors:  K Elisabet Ohlin; Irene Sebastianutto; Chris E Adkins; Cornelia Lundblad; Paul R Lockman; M Angela Cenci
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

2.  Role of hyperactive cerebellum and motor cortex in Parkinson's disease.

Authors:  Hong Yu; Dagmar Sternad; Daniel M Corcos; David E Vaillancourt
Journal:  Neuroimage       Date:  2007-01-12       Impact factor: 6.556

3.  Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.

Authors:  Xiomara A Perez; Neeraja Parameswaran; Luping Z Huang; Kathryn T O'Leary; Maryka Quik
Journal:  J Neurochem       Date:  2008-02-01       Impact factor: 5.372

Review 4.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

5.  Modeling Parkinson's disease in primates: The MPTP model.

Authors:  Gregory Porras; Qin Li; Erwan Bezard
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

6.  Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A García-Blanco; E Herrán; A Aristieta; M Igartua; J L Pedraz; L Ugedo; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

7.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

8.  Alternative normalization methods demonstrate widespread cortical hypometabolism in untreated de novo Parkinson's disease.

Authors:  V Berti; C Polito; P Borghammer; S Ramat; L Mosconi; E Vanzi; M T De Cristofaro; M De Leon; S Sorbi; A Pupi
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-06       Impact factor: 2.346

Review 9.  Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Authors:  Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E Gross; Erwan Bezard
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

10.  Abnormal serum concentrations of proteins in Parkinson's disease.

Authors:  Ira L Goldknopf; Jennifer K Bryson; Irina Strelets; Silvia Quintero; Essam A Sheta; Miguel Mosqueda; Helen R Park; Stanley H Appel; Holly Shill; Marwan Sabbagh; Bruce Chase; Eric Kaldjian; Katerina Markopoulou
Journal:  Biochem Biophys Res Commun       Date:  2009-08-31       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.